Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full Proposal; LOI approval required)
Funding Amounts: Up to $3,000,000 total for up to 3 years; up to 10% indirect costs allowed for SRAs.
Summary: Supports clinical trials to develop and evaluate new therapies for cardiovascular disease in people with type 1 diabetes, aiming to improve outcomes and reduce risk.
Key Information: LOI approval is required before submitting a full proposal; both academic and industry applicants are eligible.